Product Description
Tamoxifen Citrate Tablets
Since last many years Saintroy Lifescience is leading manufacture, export and supplier of Tamoxifen Citrate Tablets from Surat, Gujarat, India. Tamoxifen Citrate Tablets used selective estrogen receptor modulator used to prevent breast cancer in women and treat breast cancer in women and men.
Tags: Tamoxifen Citrate Tablets manufacturer, Tamoxifen Citrate Tablets exporter, Tamoxifen Citrate Tablets supplier, Tamoxifen Citrate Tablets ,Tamoxifen Citrate potassium, whogmp approved , Tamoxifen Citrate potassium tablets manufacturer and supplier, Tamoxifen Citrate Tablets distributor, Tamoxifen Citrate Tablets drop shipper, Tamoxifen Citrate Tablets 20 mg, Tamoxifen Citrate Tablets 20 mg supplier, Tamoxifen Citrate Tablets 20 mg.
ISO/GMP/c-GMP/WHOGMP/ NAFDA Capproved, PPB Kenya approved/USFDA approved/EUGMP approved/MOH Iran approved manufacturing facility in Gujarat, India.
Registration: Saintroy Lifescience is interested in registration of own brand or customer brands in ministry of health of clients country and we also provide the products samples, COA, COPP, ACTD or CTD Dossier, DMF, Manufacturing license, Free sales certificate and other required documents.
Export Country : Saintroy Lifescience Tamoxifen Citrate Tablets export to USA, Canada, Germany, Europe, France, Ghana, Nigeria, Kenya, Senegal, Sudan,UAE, Kuwait, Dubai, Cameroon, Lebanon, Peru, Chile, Somalia, Philippines,Myanmar, Maldives, Thailand, Singapore, Malaysia, Hong Kong, China, Zimbabwe,Togo, Burkina Faso, Niger, Guinea Bissau, Congo, Democratic of republic, IvoryCosta, Oman, Guatemala, Nicaragua, Salvador, Qatar, Costa Rica, Panama, Cuba,Colombia, Bolivia, Argentine, Algeria, Guyana, Morocco, Jordan, Bahrain, Iran,Egypt, Kyrgyzstan, Uzbekistan, Kazakhstan.
Comprehensive Cancer TherapyTamoxifen Citrate Tablets are renowned for their role in managing hormone receptor-positive breast cancer. They work by interfering with the effects of estrogen in breast tissue, restricting cancer cell growth. These tablets are part of comprehensive cancer therapy regimens in India and globally, supported by reliable storage guidelines and an assured shelf life.
Quality Assurance and StorageEach batch of Tamoxifen Citrate Tablets undergoes stringent quality checks to guarantee potency and purity. The tablets are to be stored in a cool and dry place to maintain their effectiveness throughout the two-year shelf life. This attention to storage and environmental control ensures prolonged product integrity for users and healthcare providers.
FAQ's of Tamoxifen Citrate Tablets:
Q: How should Tamoxifen Citrate Tablets be stored for best results?
A: Tamoxifen Citrate Tablets should be kept in a cool, dry place to maintain their efficacy and ensure a stable shelf life of two years. Avoid exposure to direct sunlight and excessive moisture.
Q: What are the primary uses of Tamoxifen Citrate Tablets?
A: These tablets are mainly prescribed for the prevention and treatment of hormone receptor-positive breast cancer. They act by blocking estrogen receptors in breast tissue, thus inhibiting tumor growth.
Q: When is Tamoxifen Citrate administered during cancer therapy?
A: Tamoxifen Citrate Tablets are typically started after the initial diagnosis and as part of ongoing therapy, as prescribed by an oncologist. The duration of treatment may vary based on patient-specific protocols.
Q: Where are Tamoxifen Citrate Tablets manufactured and supplied from?
A: These tablets are manufactured, distributed, and exported by pharmaceutical companies across India, serving hospitals, clinics, and wholesalers both domestically and internationally.
Q: What is the recommended process for using Tamoxifen Citrate Tablets?
A: Tablets should be taken exactly as directed by a healthcare professional, usually once daily. Adhering to prescribed timing and dosage is crucial for optimal therapeutic outcomes.
Q: How does Tamoxifen Citrate benefit cancer patients?
A: Tamoxifen Citrate blocks the effects of estrogen in breast tissue, helping reduce the risk of cancer recurrence and increase survival rates among eligible patients.